OriginGene-tech Launches China's First Microfluidic Electrochemical CDMO Service Platform

What sparks will fly when electrochemistry meets microfluidics? Let’s first take a look at these two technologies.

Microfluidics TechnologyDue to their characteristics of miniaturization and integration, microfluidic devices are typicallyKnown as "microfluidic chips" or "Lab-on-a-chip". It is on a piece ofA few square centimeters or even smalleron the chipBuilding a Micro-Laboratory Analysis Platform, integrating basic operational units involved in fields such as biology and chemistry—including sample preparation, reaction, separation, detection, cell culture, sorting, and lysis—onto a tiny chip. A network of microchannels forms the core structure, allowing controllable fluid flow to permeate the entire system, thereby realizing various functions of conventional chemical or biological laboratories. This enables rapid and accurate processing, detection, and analysis of proteins, nucleic acids, cells, and other specific targets.

ElectrochemistryAs a branch of chemistry, it is a new generation of IVD technology that achieves an order-of-magnitude reduction in cost. However, it is less understood in China and is often confused with the concept of electrochemiluminescence. Compared to electrochemiluminescence,Electrochemical sensing replaces optical detection, eliminating photoelectric losses and obviating the need for complex and expensive optical components., whileEnsures real-time signal transmission, requires no complex preprocessing, and integrates with microfluidics technology, making it more suitable for point-of-care rapid testing.。

Currently, products from international electrochemical IVD companies have not yet entered the Chinese market, whileElectrochemical technology presents high barriers to entry, with few domestic companies deeply engaged in achieving breakthroughs.. OriginGene-tech targets the currently unmet application needs in the IVD sector by exploring the integration of microfluidics with emerging technologies, unlocking the potential of new application scenarios, and pursuing a decentralized strategy to differentiate its presence in primary healthcare markets, thereby driving the research and development of microfluidic products. It focuses on achieving high sensitivity, rapid detection, and portability.Pioneered the integrated application of electrochemistry and microfluidics in China, having achieved breakthroughs in core microfluidic electrochemical technologies.

OriginGene-tech Microfluidic Electrochemical PlatformThe first-generation research prototype was assembled in June 2021. In May 2023, on the basis of completing the development of core components for electrochemical signal acquisition and proprietary consumables for microfluidic electrode chips, the companyResearch Edition Taiji Mini Handheld Electrochemical Detector Launched, and the integrated development of commercial IVD instruments is nearing completion.

On Thursday, July 18, at 19:30, the 76th session of VCBeat Select New Product Review will feature Zhu Kun, Founder and General Manager of Beijing OriginGene-tech Biotechnology Co., Ltd., and Jin Dazhi, Director of the Zhejiang Provincial Key Laboratory for Biomarkers and In Vitro Diagnostics Translation."China's First Microfluidic Electrochemical CDMO Service Platform"Product Introduction.

Scan the QR code on the poster to add the assistant and schedule a live stream.

Zhu Kun

Founder and General Manager of Beijing OriginGene-tech Biotechnology Co., Ltd.

Guest Researcher at the Xiamen Institute of Rare Earth Materials, Chinese Academy of Sciences; Standing Committee Member of the Biological Diagnostic Technology Branch of the China Medical Biotechnology Association; Committee Member of the Labelled Immunoassay Professional Committee of the China Association for Analysis and Testing; Director of the Animal Infectious Diseases Branch of the Chinese Society of Animal Husbandry and Veterinary Medicine; Leading Talent in Suzhou High-Tech Industrial Development Zone.

Over 20 years of experience in the genetic engineering pharmaceuticals and in vitro diagnostics (IVD) industries. Successfully obtained clinical trial approval for "Recombinant Human Interleukin-11" as a new drug and completed its technology transfer. Organized the application process and secured more than 70 registration certificates for Class II and Class III medical devices. A practitioner of multiple novel molecular diagnostic technologies; notably, the multiplex PCR capillary electrophoresis technology was included in the special program for the Nanjing Youth Olympic Games, awarded the Second Prize of the Jiangsu Provincial Preventive Medicine Science and Technology Award, and established as an industry group standard. The rapid PCR product received the Second Prize of the China Industry-University-Research Cooperation Innovation Achievement Award, while the microfluidic electrochemical detection platform filled a domestic gap in this field. Previously undertook or participated in nine national, provincial, and municipal research projects.

Jin Dazhi

Director, Zhejiang Provincial Key Laboratory of Biomarkers and In Vitro Diagnostics Translation

Ph.D. in Science, Researcher, Master’s Supervisor; Director of the Zhejiang Provincial Key Laboratory for Biomarkers and In Vitro Diagnostics Translation, Hangzhou Medical College (School of Laboratory Medicine and School of Bioengineering); Director of the Institute of Clinical Microbiology, Hangzhou Medical College; Postdoctoral Fellow at Vanderbilt University, USA; Visiting Scholar at Memorial Sloan Kettering Cancer Center, USA; Expert Reviewer for Medical Devices at the Center for Medical Device Evaluation, National Medical Products Administration; Standing Committee Member of the Branch of Biomedical Diagnostic Technology, China Medical Biotechnology Association; Standing Committee Member of the Professional Committee on Clinical Microbiology Laboratories, Chinese Hospital Association, etc.

Presided over projects that won the Second and Third Prizes of the Zhejiang Provincial Science and Technology Progress Award. Selected as a Leading Talent in Scientific and Technological Innovation of Zhejiang Province, a Health Innovation Talent of Zhejiang Province, and other similar distinctions. Presided over projects funded by the National Natural Science Foundation of China, Key Projects of the Zhejiang Provincial Natural Science Foundation, Zhejiang Provincial Key Research and Development Programs, and Major Projects Co-constructed by the Provincial and Ministerial Authorities. Published more than 40 SCI-indexed papers in journals such as Cell, EMI, and JCM; granted 13 national invention patents, 2 utility model patents, and 5 software copyrights.

Beijing OriginGene-tech Biotechnology Co., Ltd., established in July 2018, is a high-tech enterprise integrating the R&D, manufacturing, sales, and services of in vitro diagnostic (IVD) reagents and associated instruments. As the first company in China to develop a microfluidic electrochemical detection platform, it has been recognized as a National High-Tech Enterprise, a “Specialized, Refined, Differential, and Innovative” SME, a National Technology-Based SME, a Zhongguancun High-Tech Enterprise, a Zhongguancun Golden Seed Enterprise, and a Beijing Intellectual Property Pilot Unit. Its R&D and production facilities cover a total area of 2,500 square meters. Globally, only four to five companies have achieved commercialization of electrochemical detection for macromolecules such as nucleic acids and proteins.

Beijing OriginGene-tech Biotechnology Co., Ltd. stands at the forefront of the commercialization of electrochemical biosensing in China, having established a unique domestic supply chain system tailored for microfluidics and electrochemistry. The company has forged partnerships or letters of intent with over 30 universities, research institutes, and enterprises across China. As a strategic reserve project for the military, it has signed an agreement for customized product development with the armed forces. Looking ahead, Beijing OriginGene-tech will collaborate with its partners to build an ecosystem for microfluidic electrochemical detection.

“Artery Select New Product Debut” is a live-streaming program under the “Artery Select” brand, dedicated to supporting medical enterprises in launching innovative products. The program’s mission is: to empower the milestone launch of every innovative medical product.

Scan the QR code below to contact the assistant and schedule a live stream (if you have already added them, please reach out to the assistant directly)

Scan the QR code below to download the VCBeat app and register to watch the live stream.

Contact the assistant and send a screenshot of the live stream to enter the lucky draw for a chance to win a [15-day trial membership of VBInsight Industry Think Tank].